Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05572515 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 614
- Enrollment target
- 20
- Study locations
NCT05572515 is a Phase 3 study of Relapsed or Refractory Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 614 participants, above the 281-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (119% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05572515, a Phase 3 study of Relapsed or Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 614 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Carfilzomib
- DRUG Bortezomib
Study Locations (20)
California
- Alta Bates Comprehensive Cancer Center - Berkeley
- MemorialCare Long Beach Medical Center - Long Beach
- University of California Irvine - Orange
- PIH Health Hospital - Whittier
Florida
- University of Miami Sylvester Cancer Center - Miami
- Orlando Health Cancer Institute - Orlando
- Cleveland Clinic Florida - Weston
Maryland
- Walter Reed National Military Medical Center - Bethesda
- Maryland Oncology Hematology P A - Silver Spring
Alaska
- Alaska Oncology and Hematology LLC - Anchorage
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Colorado
- Rocky Mountain Cancer Centers - Aurora
Connecticut
- University of Connecticut - Farmington
Iowa
- Mission Cancer Blood - Waukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2023-03-29 |
| Est. Completion | 2031-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05572515
The ClinicalTrials.gov registry entry for NCT05572515 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 281-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (119% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Teclistamab is the first listed.
NCT05572515 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT05572515 about?
NCT05572515 is a clinical study titled "A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
What is the current status of trial NCT05572515?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2023-03-29. Estimated completion is 2031-08-31.
What conditions does trial NCT05572515 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05572515?
The interventions under investigation include: Teclistamab (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT05572515?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05572515 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
RECRUITING · Phase 3
-
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
ACTIVE NOT RECRUITING · Phase 3
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.